Document text
Principal Investigator: Peter Leif Bergsagel
Organization: MAYO CLINIC ARIZONA
Fiscal Year: 2024
Award: $2,098,348
Funding agency: National Cancer Institute
PROJECT SUMMARY/ABSTRACT
The Mayo Clinic Multiple Myeloma SPORE (SPORE) is a dynamic, productive, translational cancer research
program based at all three Mayo Clinic sites (Rochester MN, Jacksonville FL, Phoenix AZ), now with input from
the Princess Margaret Cancer Centre in Toronto, Ontario. From 2003-2013 we participated in the joint
DFCI/Mayo Clinic Multiple Myeloma SPORE, and since 2015 in the Mayo Clinic Multiple Myeloma SPORE. At
the center of the ongoing success of the SPORE is the collaborative interaction between investigators
throughout the Mayo Foundation, as well as SPORE basic laboratory, translational and clinical investigators
and patient advocates focused on MM. The overall goal of the SPORE is to support innovative, interactive,
rigorous translational myeloma research that leverages the expertise of laboratory, translational and clinical
expertise. Over the last funding period, the SPORE has been highly productive as demonstrated by
identification of new tumor markers and prognostic indices that are being used clinically; scientific findings that
led to innovative clinical trials both within and outside the SPORE; multiple publications with many authored by
investigators from multiple sites; and brisk accrual to translational clinical trials. The SPORE was involved in
multiple productive vertical and horizontal collaborations with other national and international academic
institutions and organizations. For example, with leadership of clinical efforts in patient-focused clinical trials
from the Multiple Myeloma Research Foundation, International Myeloma Foundation, and MyelomaCrowd. The
current proposal includes 3 major research projects. Two of the projects are new, based on research results
obtained over the past funding period, while Project 1 is a continuation of efforts to investigate ways of
modulating the immune micro-environment to improve the efficacy of oncolytic viral therapy in MM in a phase I
clinical trial. Project 2 is an integrated multi-omic analysis of high-risk MM with associated clinical trial highly
focused on identifying promising approaches in this group of patients that have not benefited from recent
advances. Project 3 is investigating the genetic and microenvironmental mechanisms of progression of
smoldering MM to MM to enable early detection of MM requiring treatment. The SPORE also includes
Developmental Research and Career Enhancement Programs to pursue novel translational concepts in MM
research and new investigators through the programs respectively. Finally, the SPORE will enhance the
infrastructure that supports translational MM research through shared core resources in Administration,
Biostatistics & Bioinformatics, and Biospecimens & Clinical Database.
Terms: <Advocate><Area><Arizona><Basic Research><Basic Science><Benign><Bi-specific antibodies><Bifunctional Antibodies><Bio-Informatics><Bioinformatics><Biological Specimen database><Biology><Biometrics><Biometry><Biostatistics><Bispecific Antibodies><Cancer Center><Cancer Research Programs><Cancer Research Project><Caring><Clinic><Clinical><Clinical Investigator><Clinical Research><Clinical Study><Clinical Trials><Collaborations><Comprehensive Cancer Center><Development><Dysfunction><Early Diagnosis><Early-Stage Clinical Trials><Florida><Foundations><Functional disorder><Funding><Genetic><Goals><Host Factor><Host Factor Protein><Immune mediated therapy><Immune response><Immunological response><Immunologically Directed Therapy><Immunomodulation><Immunotherapy><Infrastructure><Institution><Integration Host Factors><International><Investigators><Joints><Laboratories><Leadership><Malignant><Malignant - descriptor><Minnesota><Multiple Myeloma><Ontario><Patients><Peer Review><Peer Review Grants><Phase 1 Clinical Trials><Phase I Clinical Trials><Physiopathology><Plasma-Cell Myeloma><Prevention><Productivity><Prognosis><Publications><R-Series Research Projects><R01 Mechanism><R01 Program><Regimen><Research><Research Grants><Research Personnel><Research Project Grants><Research Projects><Research Resources><Research Support><Researchers><Resources><Risk><Scientific Publication><Site><TM-MKR><Translating><Tumor Biology><Tumor Markers><VSV><Vesicular Stomatitis Virus><Vesicular stomatitis Indiana virus><Virotherapeutics><Virotherapy><Work><biorepository database><biosample database><biospecimen database><bsAb><cancer microenvironment><cancer virotherapy><career><clinical database><clinical epidemiology><developmental><early detection><high risk><host response><immune microenvironment><immune modulation><immune regulation><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><improved><innovate><innovation><innovative><multiomics><multiple omics><myeloma><myelomatosis><novel><oncolytic viral therapeutic><oncolytic viral therapy><oncolytic virotherapeutic><oncolytic virotherapy><oncolytic virus therapy><panomics><pathophysiology><phase I protocol><prognostic index><programs><sound><specimen database><success><survivorship><therapy optimization><translational cancer research><translational clinical trial><translational investigator><translational researcher><translational scientist><treatment optimization><tumor biomarker><tumor immune microenvironment><tumor microenvironment><tumor specific biomarker><tumor-immune system interactions>